Urothelial Carcinoma
📧 Sign up to get email alerts when something new happens for Urothelial Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors [Phase 1]
Pfizer's Phase 1 study PF-08046876 is recruiting adults with various advanced solid tumors to evaluate safety and dosing. The trial includes…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder [Phase 2]
Phase 2 trial evaluating nivolumab with and without urelumab in cisplatin-ineligible or chemotherapy-refusing patients with muscle-invasive …
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors [Phase 1]
Phase 1 clinical trial update for IDE892 evaluating monotherapy and combination in MTAP-deleted advanced solid tumors. The study is currentl…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors [Phase 1]
Phase 1 clinical trial of ZM008, an anti-LLT1 antibody, given as a single agent and then in combination with toripalimab in patients with ad…
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
The document reports the completion of a non-interventional study evaluating avelumab in patients with advanced or metastatic urothelial car…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 substudy of pembrolizumab (MK-3475) and other investigational PD-1/PD-L1 agents in PD-1/PD-…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue
This ClinicalTrials.gov entry describes the NCI-sponsored study NCT02379429, a trial focusing on care of urothelial cancer patients and pros…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy [Phase 2]
A Phase 2 clinical trial evaluates trastuzumab in combination with serplulimab and chemotherapy for HER2-overexpressing unresectable locally…
-
EMA approval · 2026-03-30EMA Authorised: Tecentriq (atezolizumab) — Roche Registration GmbH
The European Medicines Agency authorized Tecentriq (atezolizumab) by Roche Registration GmbH for multiple cancer indications, including non-…
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer [Phase 2]
Phase 2 study evaluating sacituzumab govitecan as neoadjuvant therapy before radical cystectomy for muscle-invasive bladder cancer has compl…
-
CLINICAL_TRIALS trial_result · 2026-03-25Clinical Trial Update: Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma [Phase 1]
Phase 1 clinical trial evaluating dual-target Nectin-4/HER2 CAR-NK cells for advanced urothelial carcinomas, including bladder cancer, is cu…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 [Phase 1]
Phase 1/1b trial evaluating RNDO-564 as a single agent or in combination with pembrolizumab in bladder cancer and nectin-4–associated solid …
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors [Phase 1]
Open-label Phase 1 study evaluating BL-M07D1 in HER2-expressing malignant solid tumors, with recruitment across several tumor types includin…
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy [Phase 3]
Phase 3 trial update evaluating the optimal duration of immune checkpoint therapy for locally advanced and metastatic urothelial carcinoma; …
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Diagnostic Values of Urothelial Carcinomas: Single-bolus Versus Split-bolus Computed Tomography Urography [NA]
Clinical trial update evaluating diagnostic values of single-bolus versus split-bolus CT urography for urothelial carcinoma. The study is sp…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors. [Phase 1, Phase 2]
A phase 1/2 clinical trial is evaluating the combination of BGB-A445 with tislelizumab in patients with select advanced solid tumors, includ…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors
A clinical trial is investigating whether Galectin-3 levels predict outcomes in patients with renal cell carcinoma, urothelial carcinoma, no…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors [Phase 1, Phase 2]
A Phase 1/2 clinical trial update shows ALE.P03 as monotherapy being studied in adults with selected advanced or metastatic CLDN1+ solid tum…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Bio Clinical Collection of Urothelial Carcinoma
This clinical trial update describes the Bio Clinical Collection of Urothelial Carcinoma trial, sponsored by University Hospital, Toulouse, …
-
CLINICAL_TRIALS other · 2026-03-19Clinical Trial Update: Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma [Phase 2]
Phase 2 clinical trial update for enfortumab vedotin in urothelial carcinoma describes schedule de-escalation in metastatic/locally advanced…
-
EMA approval · 2026-03-18EMA Authorised: Opdivo (nivolumab) — Bristol-Myers Squibb Pharma EEIG
EMA authorised Opdivo (nivolumab) for multiple cancer indications, including melanoma, Hodgkin lymphoma, renal cell carcinoma, non-small cel…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors [Phase 1]
This update reports on a Phase 1 trial testing the combination of sonidegib and pembrolizumab in patients with various advanced solid tumors…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors [Phase 1, Phase 2]
This clinical trial update reports that GI Innovation is studying GI-101 and GI-101A as single agents or in combination with pembrolizumab o…
-
CLINICAL_TRIALS withdrawal · 2026-03-17Clinical Trial Update: N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer [Phase 1]
A phase 1 trial evaluating N-803 in combination with pembrolizumab and enfortumab vedotin for urothelial cancer has been withdrawn.
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread [Phase 2]
A Phase 2 clinical trial evaluating Sacituzumab Govitecan in patients with metastatic urothelial carcinoma that cannot be removed or has spr…